---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: PARP inhibitors"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: PARP inhibitors. Topics: Olaparib monotherapy: FDA-approved indication after enzalutamide or abiraterone; Olaparib monotherapy: PROfound efficacy, cohort A; Olaparib monotherapy: PROfound primary publication; Olaparib monotherapy: PROfound overall survival publication; 11 further topics. 15 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/parp-inhibitors"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: PARP inhibitors

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 PARP Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

### Olaparib monotherapy: FDA-approved indication after enzalutamide or abiraterone

> “Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.”

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### Olaparib monotherapy: PROfound efficacy, cohort A

| Outcome | Olaparib (n=162) | Enzalutamide or abiraterone acetate (n=83) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “7.4 (6.2, 9.3)” | “3.6 (1.9, 3.7)” |
| rPFS hazard ratio (95% CI) | “0.34 (0.25, 0.47)” | Not applicable |
| Median OS, months (95% CI) | “19.1 (17.4, 23.4)” | “14.7 (11.9, 18.8)” |
| OS hazard ratio (95% CI) | “0.69 (0.50, 0.97)” | Not applicable |

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### Olaparib monotherapy: PROfound primary publication

> “We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).”
> “In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001)”
> “Anemia and nausea were the main toxic effects in patients who received olaparib.”

Source: [de Bono et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32343890/)

<a id="topic-2.2.2.1.4-4"></a>

### Olaparib monotherapy: PROfound overall survival publication

> “The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P = 0.02).”
> “In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5 months with control therapy.”
> “Overall, 86 of 131 patients (66%) in the control group crossed over to receive olaparib (56 of 83 patients [67%] in cohort A).”

Source: [Hussain et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32955174/)

<a id="topic-2.2.2.1.4-5"></a>

### Rucaparib: FDA-approved indication after androgen receptor-directed therapy

> “for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy.”

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### Rucaparib: TRITON3 efficacy, BRCA-mutated subgroup

| Outcome | Rucaparib (N=201) | Androgen receptor pathway inhibitor or docetaxel (N=101) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “11.2 (9.2-13.8)” | “6.4 (5.4-8.3)” |
| rPFS hazard ratio (95% CI) | “0.50 (0.36, 0.69)” | Not applicable |
| Median OS, months (95% CI) | “23.2 (19.1, 25.2)” | “21.2 (18.0, 23.1)” |
| OS hazard ratio (95% CI) | “0.91 (0.68, 1.20)” | Not applicable |
| Overall response rate, % (95% CI) | “45.1 (34.1, 56.5)” | “17.1 (7.2, 32.1)” |

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

### Rucaparib: TRITON3 crossover and ATM subgroup

> “In an exploratory analysis in the subgroup of 103 (25%) patients with ATM mutations, the rPFS hazard ratio was 0.95 (95% CI: 0.59, 1.52) and the OS hazard ratio was 1.21 (95% CI: 0.77, 1.90), indicating that the improvement in the overall population was primarily attributed to the results seen in the subgroup of patients with BRCAm.”
> “Of patients with BRCAm who were randomized to receive ARPI or docetaxel (n=101), 52% crossed over to receive RUBRACA after disease progression.”

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

<a id="topic-2.2.2.1.4-8"></a>

### Rucaparib: TRITON3 comparisons with docetaxel and with a second inhibitor

> “In the BRCA subgroup, the median duration of imaging-based progression-free survival was longer with rucaparib than with docetaxel (11.2 months vs. 8.3 months; hazard ratio, 0.53; 95% CI, 0.37 to 0.77)”
> “the median duration was also longer with rucaparib than with abiraterone acetate or enzalutamide (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% CI, 0.25 to 0.58)”

Source: [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/)

<a id="topic-2.2.2.1.4-9"></a>

### Guideline statements on PARP inhibitors in pretreated disease

> “Offer poly(ADP-ribose) polymerase (PARP) inhibitor monotherapy to pre-treated mCRPC patients with relevant DNA repair gene mutations.”
> “In case of a known BRCA alteration, the use of a PARP inhibitor should always be prioritised as these patients harbour an adverse prognosis and don’t respond well to most other treatments.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.4-10"></a>

### First-line combination in inhibitor-naive disease: olaparib with abiraterone

> “Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration- resistant prostate cancer (mCRPC).”
> “Patients with prior treatment with abiraterone were excluded.”

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

| Outcome (BRCA-mutated subgroup, exploratory) | Olaparib plus abiraterone (N = 47) | Placebo plus abiraterone (N = 38) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “NR (NR, NR)” | “8 (6, 15)” |
| rPFS hazard ratio (95% CI) | “0.24 (0.12, 0.45)” | Not applicable |
| Median OS, months (95% CI) | “NR (NR, NR)” | “23 (18, 34)” |
| OS hazard ratio (95% CI) | “0.30 (0.15, 0.59)” | Not applicable |

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.4-11"></a>

### First-line combination in inhibitor-naive disease: PROpel publication

> “We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting.”
> “At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001)”

Source: [Clarke et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319800/)

<a id="topic-2.2.2.1.4-12"></a>

### First-line combination: talazoparib with enzalutamide

> “metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test”

Source: [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)

| Outcome (TALAPRO-2, HRR gene-mutated) | Talazoparib with enzalutamide (N=200) | Placebo with enzalutamide (N=199) |
| --- | --- | --- |
| Median rPFS by BICR, months (95% CI) | “NR (21.9, NR)” | “13.8 (11.0, 16.7)” |
| rPFS hazard ratio (95% CI) | “0.45 (0.33, 0.61)” | Not applicable |
| Median OS, months (95% CI) | “45.1 (35.4, NR)” | “31.1 (27.3, 35.4)” |
| OS hazard ratio (95% CI) | “0.62 (0.48, 0.81)” | Not applicable |

Source: [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)

<a id="topic-2.2.2.1.4-13"></a>

### First-line combination: TALAPRO-2 all-comers publication

> “TALAPRO-2 is a randomised, double-blind, phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy in men (age ≥18 years [≥20 years in Japan]) with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy.”
> “At the planned primary analysis, median rPFS was not reached (95% CI 27·5 months-not reached) for talazoparib plus enzalutamide and 21·9 months (16·6-25·1) for placebo plus enzalutamide (hazard ratio 0·63; 95% CI 0·51-0·78; p<0·0001).”

Source: [Agarwal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285865/)

<a id="topic-2.2.2.1.4-14"></a>

### First-line combination: niraparib with abiraterone acetate

> “AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).”

Source: [Akeega prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf)

| Outcome (MAGNITUDE, BRCA-mutated subgroup) | Niraparib with abiraterone acetate (N=113) | Placebo with abiraterone acetate (N=112) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “16.6 (13.9, NE)” | “10.9 (8.3, 13.8)” |
| rPFS hazard ratio (95% CI) | “0.53 (0.36, 0.79)” | Not applicable |

Source: [Akeega prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf)

<a id="topic-2.2.2.1.4-15"></a>

### Guideline statements on first-line PARP inhibitor combinations

> “Offer patients previously untreated for mCRPC and harbouring an HRR or breast cancer gene ( BRCA ) mutation abiraterone in combination with olaparib if the patient is fit for both agents and did not previously receive an ARPI.”
> “Offer patients previously untreated for mCRPC and harbouring a BRCA mutation abiraterone in combination with niraparib if the patient is fit for both agents and did not previously receive an ARPI.”
> “Offer patients previously untreated for mCRPC and harbouring an HRR mutation enzalutamide in combination with talazoparib, if the patient is fit for both agents and did not previously receive an ARPI.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf); [Agarwal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40683290/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
